|
|
|
|
|
(State or other jurisdiction
of incorporation) |
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification) |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
Exhibit
Number
|
Description
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
ENTERA BIO LTD.
|
|||
Date: March 31, 2023
|
By:
|
/s/ Miranda Toledano
|
|
Name: Miranda Toledano
Title: Chief Executive Officer
|
• |
In June 2021, Entera reported positive results from its double-blind, placebo-controlled Phase 2 study of EB613 in 161 post-menopausal women with low BMD and osteoporosis. The study met all PD/ biomarker, BMD endpoints, and demonstrated a
generally well tolerated safety profile. It was also noted that EB613 had a differentiated biomarker and BMD profile versus historical 6-month data reported with daily subcutaneous injections of Forteo® in a similar population.
|
• |
In January 2022, Entera received FDA’s End of Phase 2 meeting minutes which conveyed concern with the previously proposed Phase 3 study, based on a 12-month non-inferiority head-to-head design versus Forteo® and whether such a trial would
be successful.
|
• |
In response to the FDA’s End of Phase 2 minutes, Entera re-designed the proposed phase 3 to
potentially align with FDA’s suggestion to explore a placebo-controlled phase 3 design with a Total Hip BMD (TH BMD) endpoint, given emerging seminal publications from the FNIH BQP-ASBMR project.
|
• |
On July 18th, 2022, Entera announced that the FDA had granted Entera’s request for a Type C Meeting based on the revised phase 3 registrational protocol for EB613.
|
• |
On October 6th 2022, Entera announced the conclusion of its Type C meeting and concurrence with the FDA that a single well designed Phase 3 placebo-controlled study with a proposed primary endpoint of TH BMD may support a New
Drug Application (NDA) submission of EB613; and that a relative PK study comparing its oral tablet form of teriparatide, EB613 versus the subcutaneous injection of teriparatide, Forteo®, may be utilized as a scientific bridge to support the
505(b)(2) NDA pathway.
|
• |
On February 15th, 2023, Entera announced that a Type D meeting had been accepted by the FDA. As part of its briefing documents for the Type D process, Entera aimed to confirm that the protocol fully met FDA’s expectations,
including the analysis of the primary TH BMD endpoint and the population PK evaluations.
|
ENTERA BIO LTD.
|
CONSOLIDATED BALANCE SHEETS
|
(U.S. dollars in thousands, except share data)
|
(Unaudited)
|
December 31
|
December 31
|
|||||||
2022
|
2021
|
|||||||
Cash and cash equivalents
|
12,309
|
24,892
|
||||||
Accounts receivable and other current assets
|
540
|
437
|
||||||
Property and equipment, net
|
139
|
156
|
||||||
Other assets, net
|
139
|
502
|
||||||
Total assets
|
13,127
|
25,987
|
||||||
Accounts payable and other current liabilities
|
1,341
|
3,161
|
||||||
Total non-current liabilities
|
32
|
261
|
||||||
Total liabilities
|
1,373
|
3,422
|
||||||
Total shareholders' equity
|
11,754
|
22,565
|
||||||
Total liabilities and shareholders' equity
|
13,127
|
25,987
|
Year ended
December 31,
|
||||||||
2022
|
2021
|
|||||||
REVENUES
|
134
|
571
|
||||||
COST OF REVENUES
|
101
|
373
|
||||||
GROSS PROFIT
|
33
|
198
|
||||||
OPERATING EXPENSES:
|
||||||||
Research and development
|
5,848
|
6,771
|
||||||
General and administrative
|
7,253
|
5,690
|
||||||
Other income
|
(51
|
)
|
(46
|
)
|
||||
TOTAL OPERATING EXPENSES
|
13,050
|
12,415
|
||||||
OPERATING LOSS
|
13,017
|
12,217
|
||||||
FINANCIAL EXPENSES (INCOME), net
|
(83
|
)
|
29
|
|||||
LOSS BEFORE INCOME TAX
|
12,934
|
12,246
|
||||||
INCOME TAX EXPENSE ָ(BENEFIT)
|
137
|
(59
|
)
|
|||||
NET LOSS
|
13,071
|
12,187
|
||||||
LOSS PER SHARE BASIC AND DILUTED
|
0.45
|
0.47
|
||||||
WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
|
28,808,090
|
28,133,770
|